Lion Street Advisors LLC Increases Holdings in AstraZeneca PLC (NASDAQ:AZN)

Lion Street Advisors LLC boosted its position in AstraZeneca PLC (NASDAQ:AZN) by 13.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,777 shares of the company’s stock after purchasing an additional 665 shares during the period. Lion Street Advisors LLC’s holdings in AstraZeneca were worth $379,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the company. McClarren Financial Advisors Inc. boosted its stake in AstraZeneca by 320.8% in the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of AstraZeneca in the third quarter valued at about $28,000. Ashton Thomas Securities LLC purchased a new position in shares of AstraZeneca in the third quarter valued at $45,000. Albion Financial Group UT grew its stake in shares of AstraZeneca by 68.9% during the fourth quarter. Albion Financial Group UT now owns 608 shares of the company’s stock valued at $40,000 after acquiring an additional 248 shares in the last quarter. Finally, Hollencrest Capital Management grew its stake in AstraZeneca by 38.4% during the 3rd quarter. Hollencrest Capital Management now owns 692 shares of the company’s stock valued at $54,000 after purchasing an additional 192 shares in the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $89.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $70.93 on Thursday. The firm’s 50 day moving average is $67.20 and its two-hundred day moving average is $73.72. The firm has a market capitalization of $219.96 billion, a P/E ratio of 33.94, a PEG ratio of 1.18 and a beta of 0.46. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion during the quarter, compared to analyst estimates of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.87 EPS. Analysts anticipate that AstraZeneca PLC will post 4.13 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.